Categories: Genetic diseases, Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Aspergillosis

MalaCards integrated aliases for Aspergillosis:

Name: Aspergillosis 56 12 74 52 58 54 42 3 43 15 17 71 32
Aspergillosis, Susceptibility to 56 29 13 6 39
Infection Due to Aspergillus 12


Orphanet epidemiological data:

Inheritance: Not applicable; Age of onset: All ages;


Orphanet: 58  
Rare infectious diseases

External Ids:

Disease Ontology 12 DOID:13564
OMIM 56 614079
ICD9CM 34 117.3
MeSH 43 D001228
NCIt 49 C2886
SNOMED-CT 67 65553006
ICD10 32 B44 B44.9
MESH via Orphanet 44 D001228
ICD10 via Orphanet 33 B44.0 B44.1 B44.2 more
UMLS via Orphanet 72 C0004030
Orphanet 58 ORPHA1163
UMLS 71 C0004030

Summaries for Aspergillosis

NIH Rare Diseases : 52 Aspergillosis is an infection, growth, or allergic response caused by the Aspergillus fungus. There are several different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA), a condition where the fungus causes allergic respiratory symptoms similar to asthma, such as wheezing and coughing, but does not actually invade and destroy tissue . Another kind of aspergillosis is invasive aspergillosis. This infection usually affects people with weakened immune systems due to cancer , AIDS, leukemia, organ transplantation, chemotherapy , or other conditions or events that reduce the number of normal white blood cells . In this condition, the fungus invades and damages tissues in the body. Invasive aspergillosis most commonly affects the lungs, but can also cause infection in many other organs and can spread throughout the body (commonly affecting the kidneys and brain). Aspergilloma , a growth (fungus ball) that develops in an area of previous lung disease such as tuberculosis or lung abscess , is a third kind of aspergillosis. This type of aspergillosis is composed of a tangled mass of fungus fibers, blood clots, and white blood cells . The fungus ball gradually enlarges, destroying lung tissue in the process, but usually does not spread to other areas.

MalaCards based summary : Aspergillosis, also known as aspergillosis, susceptibility to, is related to allergic bronchopulmonary aspergillosis and invasive aspergillosis, and has symptoms including fever and pruritus. An important gene associated with Aspergillosis is CLEC1A (C-Type Lectin Domain Family 1 Member A), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Guaifenesin and Benralizumab have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and liver, and related phenotypes are seizures and visual impairment

Disease Ontology : 12 An opportunistic mycosis that involves a spectrum of diseases of humans and animals caused by members of the genus Aspergillus infecting lungs, brain, kidney, heart, bone, eyes, sinuses, skin and gastrointestinal tract. It is a serious illnesses in people with a weakened immune system.

OMIM : 56 Aspergillus species are ubiquitous in nature and cause a wide spectrum of diseases, including saprophytic colonization of existing cavities (aspergilloma), allergic asthma, hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis, and disseminated disease associated with high mortality rates in patients with hematologic malignancies and recipients of solid organs and stem cell transplantations. Immunocompetent and nonatopic individuals are relatively resistant to infection, and disease occurs in the setting of host damage. Association of persistent inflammation with intractable infection is common in nonneutropenic patients after hematopoietic stem cell transplantation, as well as in allergic fungal diseases. The pathophysiology underlying Aspergillus infection highlights the bipolar nature of the inflammatory process in infection, in which early inflammation prevents or limits infection, but an uncontrolled response may oppose disease eradication (summary by Cunha et al., 2010). For information on familial occurrence of allergic bronchopulmonary aspergillosis, see 103920. (614079)

MedlinePlus : 42 Aspergillosis is a disease caused by a fungus (or mold) called Aspergillus. The fungus is very common in both indoors and outdoors. Most people breathe in the spores of the fungus every day without being affected. But some people get the disease. It usually occurs in people with lung diseases or weakened immune systems. There are different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA). Symptoms of ABPA include wheezing and coughing. ABPA can affect healthy people but it is most common in people with asthma or cystic fibrosis. Another kind is invasive aspergillosis, which damages tissues in the body. It usually affects the lungs. Sometimes it can also cause infection in other organs and spread throughout the body. It affects people who have immune system problems, such as people who have had a transplant, are taking high doses of steroids, or getting chemotherapy for some cancers. Your doctor might do a variety of tests to make the diagnosis, including a chest x-ray, CT scan of the lungs, and an examination of tissues for signs of the fungus. Treatment is with antifungal drugs. If you have ABPA, you may also take steroids. Centers for Disease Control and Prevention

CDC : 3 Aspergillosis is an infection caused by Aspergillus, a common mold (a type of fungus) that lives indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, people with weakened immune systems or lung diseases are at a higher risk of developing health problems due to Aspergillus. The types of health problems caused by Aspergillus include allergic reactions, lung infections, and infections in other organs.

Wikipedia : 74 Aspergillosis is the name given to a wide variety of diseases caused by fungal infections from species... more...

Related Diseases for Aspergillosis

Diseases in the Aspergillosis family:

Invasive Aspergillosis

Diseases related to Aspergillosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1030)
# Related Disease Score Top Affiliating Genes
1 allergic bronchopulmonary aspergillosis 34.9 SFTPD MBL2 IL5 IL4 IL10 IFNG
2 invasive aspergillosis 34.2 TLR9 TLR4 TLR2 SFTPD PTX3 MBL2
3 bronchiectasis 31.9 TLR2 MBL2 IL1B ELANE CFTR
4 hypereosinophilic syndrome 31.8 IL5 IL4 IL10 IFNG
5 mucormycosis 31.8 IFNG CSF3 CLEC7A CCR6
6 neutropenia 31.7 TLR4 MBL2 IL1B IL10 IFNG ELANE
7 graft-versus-host disease 31.6 IL1B IL10 IFNG
8 chronic granulomatous disease 31.5 TLR9 IL1B IFNG ELANE CSF3
9 cystic fibrosis 31.5 TLR4 TLR2 SFTPD MBL2 IL1B IL10
10 eosinophilic pneumonia 31.4 SFTPD IL5 IL4
11 pulmonary fibrosis 31.4 SFTPD IL1B ELANE CCL3
12 vasculitis 31.3 PTX3 MBL2 IL10 ELANE
13 rhinitis 31.3 TLR4 IL5 IL4 IL1B IL10 IFNG
14 bronchopneumonia 31.3 TLR4 IL1B IL10 ELANE
15 pulmonary tuberculosis 31.3 TLR4 TLR2 MBL2 IL4 IL1B IL10
16 acute graft versus host disease 31.3 IL4 IL10 IFNG CSF3
17 cryptococcosis 31.2 MBL2 IL4 IL10 IFNG CLEC7A CCR6
18 ige responsiveness, atopic 31.2 IL5 IL4 IL10 IFNG
19 acquired immunodeficiency syndrome 31.2 IL1B IL10 IFNG CCR6 CCL3
20 leukemia, acute myeloid 31.2 IL4 IL1B IL10 IFNG CSF3 CSF1
21 toxic shock syndrome 31.2 TLR4 TLR2 IL4 IL1B IL10 IFNG
22 purpura 31.1 IL4 IL10 IFNG
23 allergic hypersensitivity disease 31.1 SFTPD IL5 IL4 IL10 IFNG CCR6
24 sarcoidosis 1 31.1 SFTPD IL1B IFNG CCR6 CCL3
25 endocarditis 31.1 TLR2 IL10 IFNG
26 histoplasmosis 31.1 IFNG CLEC7A CCR6
27 osteomyelitis 31.1 TLR4 TLR2 IL4 IL1B IL10 IFNG
28 pneumocystosis 31.1 SFTPD CSF3 CLEC7A CCR6
29 churg-strauss syndrome 31.0 IL5 IL1B IL10
30 myelodysplastic syndrome 31.0 TLR2 IL1B IL10 IFNG CSF3 CSF1
31 respiratory failure 31.0 TLR4 SFTPD PTX3 IL5 IL1B IL10
32 candidiasis 31.0 TLR4 TLR3 TLR2 MBL2 IL4 IL1B
33 spondylitis 31.0 IL10 IFNG CCR6
34 lymphopenia 31.0 IL4 IL10 IFNG CCR6
35 chronic graft versus host disease 31.0 IL10 IFNG
36 bronchitis 31.0 TLR4 TLR2 IL5 IL4 IL1B IL10
37 pneumoconiosis 30.9 IL4 IL1B IL10
38 allergic rhinitis 30.9 IL5 IL4 IL10 IFNG
39 echinococcosis 30.9 TLR4 TLR2 IL5 IL10 IFNG
40 allergic asthma 30.9 TLR4 TLR2 IL5 IL4 IL10 IFNG
41 chronic eosinophilic pneumonia 30.9 IL5 CSF3 CCL3
42 fungal infectious disease 30.9 TLR9 TLR4 TLR3 TLR2 IL5 IL4
43 aplastic anemia 30.9 TLR9 IL4 IL1B IL10 IFNG CSF3
44 bronchiolitis obliterans 30.9 TLR4 TLR2 SFTPD IL10 IFNG
45 coccidioidomycosis 30.9 TLR4 MBL2 CLEC7A CCR6
46 uveitis 30.9 IL4 IL1B IL10 IFNG
47 immune deficiency disease 30.8 TLR9 TLR2 MBL2 IL4 IL10 IFNG
48 temporal arteritis 30.8 PTX3 IL1B IFNG CCR6
49 meningoencephalitis 30.8 TLR3 IL4 IL1B IL10 CCR6
50 fungal keratitis 30.8 TLR4 TLR2 CLEC7A

Comorbidity relations with Aspergillosis via Phenotypic Disease Network (PDN):

Bronchiectasis Bronchitis
Deficiency Anemia Heart Disease
Postinflammatory Pulmonary Fibrosis Respiratory Failure

Graphical network of the top 20 diseases related to Aspergillosis:

Diseases related to Aspergillosis

Symptoms & Phenotypes for Aspergillosis

Human phenotypes related to Aspergillosis:

58 (show top 50) (show all 56)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 seizures 58 Very rare (<4-1%)
2 visual impairment 58 Occasional (29-5%)
3 fever 58 Frequent (79-30%)
4 abnormality of the cardiovascular system 58 Occasional (29-5%)
5 dyspnea 58 Occasional (29-5%)
6 immunodeficiency 58 Frequent (79-30%)
7 sinusitis 58 Occasional (29-5%)
8 hepatitis 58 Occasional (29-5%)
9 pulmonary infiltrates 58 Frequent (79-30%)
10 pulmonary fibrosis 58 Occasional (29-5%)
11 osteomyelitis 58 Very rare (<4-1%)
12 cough 58 Very frequent (99-80%)
13 chest pain 58 Frequent (79-30%)
14 chronic obstructive pulmonary disease 58 Occasional (29-5%)
15 hemoptysis 58 Frequent (79-30%)
16 abnormality of the ribs 58 Very rare (<4-1%)
17 asthma 58 Occasional (29-5%)
18 stroke 58 Very rare (<4-1%)
19 abnormality of the kidney 58 Occasional (29-5%)
20 abnormality of the vertebral column 58 Very rare (<4-1%)
21 meningitis 58 Very rare (<4-1%)
22 neutropenia 58 Frequent (79-30%)
23 keratitis 58 Occasional (29-5%)
24 intracranial hemorrhage 58 Very rare (<4-1%)
25 headache 58 Occasional (29-5%)
26 encephalitis 58 Very rare (<4-1%)
27 eosinophilia 58 Frequent (79-30%)
28 abnormal tracheobronchial morphology 58 Very rare (<4-1%)
29 pneumonia 58 Occasional (29-5%)
30 immunologic hypersensitivity 58 Occasional (29-5%)
31 hematological neoplasm 58 Occasional (29-5%)
32 pleural effusion 58 Very rare (<4-1%)
33 abnormality of long bone morphology 58 Very rare (<4-1%)
34 pleuritis 58 Occasional (29-5%)
35 diffuse reticular or finely nodular infiltrations 58 Occasional (29-5%)
36 bronchiectasis 58 Very rare (<4-1%)
37 increased circulating total ige level 58 Occasional (29-5%)
38 functional motor deficit 58 Very rare (<4-1%)
39 dacryocystitis 58 Occasional (29-5%)
40 periorbital fullness 58 Very rare (<4-1%)
41 localized skin lesion 58 Occasional (29-5%)
42 vitritis 58 Very rare (<4-1%)
43 ocular pain 58 Occasional (29-5%)
44 abnormal esophagus morphology 58 Occasional (29-5%)
45 chronic lung disease 58 Frequent (79-30%)
46 nasal obstruction 58 Occasional (29-5%)
47 abnormality of the skull base 58 Very rare (<4-1%)
48 abnormality on pulmonary function testing 58 Frequent (79-30%)
49 rhinorrhea 58 Occasional (29-5%)
50 ground-glass opacification on pulmonary hrct 58 Frequent (79-30%)

Clinical features from OMIM:


UMLS symptoms related to Aspergillosis:

fever, pruritus

GenomeRNAi Phenotypes related to Aspergillosis according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CCL3 CCR6 CLEC7A CSF1 CSF3 IL5

MGI Mouse Phenotypes related to Aspergillosis:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.39 CCR6 CFTR CLEC7A CSF1 CSF3 ELANE
2 immune system MP:0005387 10.32 CCR6 CFTR CLEC7A CSF1 CSF3 ELANE
3 homeostasis/metabolism MP:0005376 10.31 CCR6 CFTR CLEC7A CSF1 ELANE IFNG
4 digestive/alimentary MP:0005381 10.11 CFTR CLEC7A IFNG IL10 IL4 IL5
5 integument MP:0010771 9.97 CSF1 CSF3 ELANE IFNG IL10 IL1B
6 mortality/aging MP:0010768 9.97 CFTR CLEC7A CSF1 ELANE IFNG IL10
7 liver/biliary system MP:0005370 9.86 CFTR CSF1 IFNG IL10 IL4 IL5
8 neoplasm MP:0002006 9.56 ELANE IFNG IL10 IL1B IL5 TLR2
9 respiratory system MP:0005388 9.4 CFTR CLEC7A CSF1 IFNG IL10 IL4

Drugs & Therapeutics for Aspergillosis

Drugs for Aspergillosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
2 Benralizumab Approved, Investigational Phase 4 1044511-01-4
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
Omalizumab Approved, Investigational Phase 4 242138-07-4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Mycophenolic acid Approved Phase 4 24280-93-1 446541
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
11 Antitussive Agents Phase 4
12 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
13 Trace Elements Phase 4
14 Micronutrients Phase 4
15 Vitamins Phase 4
16 Nutrients Phase 4
17 Calciferol Phase 4
18 Calcium, Dietary Phase 4
19 Antibodies, Monoclonal Phase 4
20 Immunoglobulin G Phase 4
21 Amebicides Phase 4
22 Anti-Bacterial Agents Phase 4
23 Liposomal amphotericin B Phase 4
Hydroxyitraconazole Phase 4
25 Immunoglobulins Phase 4
26 Respiratory System Agents Phase 4
27 Antibodies Phase 4
28 Anti-Allergic Agents Phase 4
29 Immunoglobulins, Intravenous Phase 4
30 Anti-Asthmatic Agents Phase 4
31 Immunoglobulin E Phase 4
32 glucocorticoids Phase 4
33 Pharmaceutical Solutions Phase 4
Calcium Nutraceutical Phase 4 7440-70-2 271
Midazolam Approved, Illicit Phase 2, Phase 3 59467-70-8 4192
deoxycholic acid Approved Phase 3 83-44-3 222528
Budesonide Approved Phase 2, Phase 3 51333-22-3 63006 5281004
Natamycin Approved Phase 3 7681-93-8 5281099
Pirfenidone Approved, Investigational Phase 2, Phase 3 53179-13-8 40632
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
43 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
Fluticasone Approved, Experimental Phase 2, Phase 3 90566-53-3 62924
Deflazacort Approved, Investigational Phase 2, Phase 3 14484-47-0
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
49 Anti-Infective Agents, Local Phase 2, Phase 3
50 Ophthalmic Solutions Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 230)
# Name Status NCT ID Phase Drugs
1 Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation Unknown status NCT00986713 Phase 4 Amphotericin B
2 Efficacy and Safety of Voriconazole for Treatment of Invasive Pulmonary Aspergillosis Secondary to COPD: a Multi-center Prospective,Open Cohort Study (VIA-COPD) Unknown status NCT02234739 Phase 4 Voriconazole
3 Prospective, Open-label Study of the Efficacy and Safety of Caspofungin for the Treatment of Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
4 A RANDOMIZED CONTROLLED STUDY OF ITRACONAZOLE IN CHRONIC CAVITARY PULMONARY ASPERGILLOSIS Completed NCT01259336 Phase 4 Itraconazole;treatment in cavitary pulmonary aspergillosis
5 A Phase 4, Open Label Study To Assess The Bronchopulmonary Pharmacokinetics Of Anidulafungin And Voriconazole Following Intravenous Administration In Healthy Subjects Completed NCT00940017 Phase 4 anidulafungin and voriconazole
6 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Completed NCT01968395 Phase 4 Caspofungin 70 mg
7 AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study. Completed NCT00334412 Phase 4 Ambisome;caspofungin
8 An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection Completed NCT00647907 Phase 4 Voriconazole
9 Pharmacokinetics of Voriconazole in Obese Subjects Completed NCT01030653 Phase 4 Voriconazole low dose;Voriconazole high dose
10 A New Dosing Regimen for Posaconazole Prophylaxis in Children Based in Body Surface Area Completed NCT02372357 Phase 4 Posaconazole prophylaxis 120 mg/m² tid
11 Prospective Double Blind Multicentre Randomized Trial of Vitamine D Estimating the Profit of a Treatment by Vitamin D3 at the Dose of 100000 UI by Comparison With a Treatment in the Dose of 12 000 UI at Renal Transplanted Patients Completed NCT01431430 Phase 4 Cholecalciferol 100 000 UI;Cholecalciferol 12 000 UI
12 Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence Therapy Completed NCT01539330 Phase 4 Voriconazole
13 Phase IV, Single-Center, Open-Label Study Evaluating the Effects of an Anti-IL5 Receptor Alpha (Benralizumab) Monoclonal Antibody in the Treatment of Severe Asthma in Patients With Allergic Bronchopulmonary Aspergillosis Recruiting NCT04108962 Phase 4 Fasenra, 30 Mg/mL Subcutaneous Solution
14 A Phase iv, Interventional, Non-blinded, Randomized Controlled Multicenter Study of Posaconazole Prophylaxis for the Prevention of Influenza-associated Aspergillosis (IAA) in Critically Ill Patients Recruiting NCT03378479 Phase 4 SOC +Posaconazole 18 MG/ML (milligram/milliliter)
15 Randomized and Multicenter Clinical Trial to Evaluate the Effectiveness and Efficiency of a Voriconazole Preemptive Genotyping Strategy in Patients With Risk of Aspergillosis Recruiting NCT04238884 Phase 4 Voriconazole preemptive genotyping strategy;Voriconazole clinical practice
16 A Randomized Controlled Trial of the Effect of Cytochrome P450 2C19 Genotype-Specific Dosing Plus TDM vs. TDM Alone on Reaching Therapeutic Voriconazole Blood Levels Recruiting NCT03731169 Phase 4 Standard of Care
17 Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection Recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
18 Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis- A Proof of Concept Study Suspended NCT03737617 Phase 4 Cuvitru 20 % Injectable Solution
19 A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Aspergillosis (CFDA Commitment) Terminated NCT02646774 Phase 4 Micafungin
20 An Exploratory, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of Multiple Doses of Omalizumab in Cystic Fibrosis Complicated by Allergic Bronchopulmonary Aspergillosis (ABPA) Terminated NCT00787917 Phase 4 Omalizumab;Placebo;Itraconazole
21 A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
22 Phase IV Open-Label Pilot Study to Evaluate the Combination of Voriconazole and Anidulafungin for the Treatment of Subjects With Proven or Probable Invasive Aspergillosis Who Are Intolerant of Polyene Treatment Terminated NCT00620074 Phase 4 voriconazole;anidulafungin
23 The Strategy Antifungal Empirical Traditional is Again Justified in Prolonged Neutropenias ". Study "PREVERT" Terminated NCT00190463 Phase 4 Amphotericin B
24 Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01282879 Phase 4 Itraconazole
25 A Double-Blind, Randomized Controlled Trial of Voriconazole (VFEND®) Plus Micafungin (MYCAMINE™) Versus Voriconazole Plus Placebo in the Treatment of Patients With Proven or Probable Invasive Aspergillosis Withdrawn NCT00423163 Phase 4 micafungin;voriconazole
26 Effectiveness of Posaconazole as Salvage Treatment After 2 Weeks of Preemptive Antifungal Treatment Withdrawn NCT02020213 Phase 4 Posaconazole
27 Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study Unknown status NCT01125644 Phase 3 SPK-843
28 Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis: a Prospective Randomized Double Masked Clinical Trial Unknown status NCT03230058 Phase 2, Phase 3 Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops
29 An Open Label Non-Comparative Study of the Safety and Efficacy of Intravenous Anidulafungin Plus AmBisome® [(Amphotericin B) Liposome for Injection] as a Treatment for Invasive Aspergillosis. Completed NCT00037206 Phase 2, Phase 3 Anidulafungin, VER002
30 Voriconazole For Primary Therapy Of Proven, Chronic Bronchopulmonary Aspergillosis, In Minimally Immunocompromised Or, Non-Immunocompromised Hosts Completed NCT00159822 Phase 2, Phase 3 Voriconazole
31 Randomized Controlled Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis Completed NCT00974766 Phase 2, Phase 3 Glucocorticoids;Glucocorticoids
32 A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069) Completed NCT01782131 Phase 3 Posaconazole;Voriconazole
33 A Multicenter, Double-Blind, Comparative Study of MK0991 (Caspofungin) Versus Micafungin in Adult Japanese Patients With Deep-seated Candida or Aspergillus Infections Completed NCT00717860 Phase 3 caspofungin acetate;Comparator: Micafungin sodium
34 A Multicentre Randomised Controlled Trial Comparing the Current Standard Diagnostic Strategy for Invasive Aspergillosis to the New Diagnostic Strategy for Invasive Aspergillosis in High-Risk Haematology Patients in Order to Determine Which Strategy Results in the Lower Rates of Use of Empiric Antifungal Therapy Completed NCT00163722 Phase 3
35 An Open Randomised Comparative Multicentre Study of the Efficacy, Safety and Toleration of Voriconazole Versus Amphotericin-B in the Treatment of Acute Invasive Aspergillosis in Immunocompromised Patients Completed NCT00003031 Phase 3 amphotericin B deoxycholate;voriconazole
36 Study of the Safety and Efficacy of AmBisome Loading Dose Regimen Vs. a Standard AmBisome Regimen for Initial Treatment of Invasive Aspergillosis and Other Filamentous Fungal Infections in Immunocompromised Patients Completed NCT00158730 Phase 3 AmBisome
37 Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi Completed NCT00634049 Phase 3 isavuconazole
38 Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis Completed NCT00001646 Phase 3 Voriconazole;Amphotericin B
39 A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal Infection Completed NCT02180165 Phase 3 Posaconazole;Voriconazole
40 A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma Completed NCT03133299 Phase 2, Phase 3 Glucocorticoids;Vitamin D
41 A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis Completed NCT01857479 Phase 2, Phase 3 Inhaled budesonide;Inhaled amphotericin
42 Nebulized Liposomal Amphotericin B (Ambisome) Versus Nebulized Placebo for the Prophylaxis of Invasive Pulmonary Aspergillosis in Haematological Patients With Prolonged Neutropenia. A Randomized Clinical Trial. Completed NCT00263315 Phase 2, Phase 3 nebulised liposomal amphotericin B
43 A Randomized Controlled Trial of Voriconazole in Allergic Bronchopulmonary Aspergillosis Completed NCT01621321 Phase 2, Phase 3 Prednisolone;Voriconazole
44 A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi. Completed NCT00412893 Phase 3 Isavuconazole;Voriconazole
45 Using Serum Galactomannan Levels in a Prospective, Randomised, Non-blinded Trial to Guide Early Anti-fungal Therapy in Haematology Patients at Risk of Invasive Aspergillosis. Completed NCT00361517 Phase 3 Amphotericin-B deoxycholate
46 Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis Completed NCT01321827 Phase 2, Phase 3 Glucocorticoids;Itraconazole
47 A Prospective, Randomized Trial Comparing The Efficacy Of Anidulafungin And Voriconazole In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Proven Or Probable Invasive Aspergillosis Completed NCT00531479 Phase 3 voriconazole;anidulafungin;voriconazole
48 An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections Completed NCT00001810 Phase 3 Voriconazole
49 A Phase III, Randomized, Double-Blind, Comparative Trial of FK463 Versus Fluconazole for Prophylaxis of Fungal Infections in Patients Undergoing a Hematopoetic Stem Cell Transplant Completed NCT00001937 Phase 3 FK463;Fluconazole
50 A Pharmacokinetic Study of JK1211 in Patients With Systemic Fungal Infection (SFI) and Patients With Febrile Neutropenia (FN) Suspected of Fungal Infection. Completed NCT00784368 Phase 3 ITCZ Oral Solution;ITCZ-IV

Search NIH Clinical Center for Aspergillosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Caspofungin acetate
Miconazole Nitrate

Cochrane evidence based reviews: aspergillosis

Genetic Tests for Aspergillosis

Genetic tests related to Aspergillosis:

# Genetic test Affiliating Genes
1 Aspergillosis, Susceptibility to 29 CLEC1A CLEC7A

Anatomical Context for Aspergillosis

MalaCards organs/tissues related to Aspergillosis:

Lung, Testes, Liver, Bone, Myeloid, Bone Marrow, Brain

Publications for Aspergillosis

Articles related to Aspergillosis:

(show top 50) (show all 12974)
# Title Authors PMID Year
Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. 61 56 6
20807886 2010
Recognition of DHN-melanin by a C-type lectin receptor is required for immunity to Aspergillus. 6 56
29489751 2018
Toll-like receptor 4 polymorphisms and aspergillosis. 56 61 54
19196681 2009
Toll-like receptor 4 polymorphisms and aspergillosis. 56 61 54
19202579 2009
Toll-like receptor 4 polymorphisms and aspergillosis. 54 61 56
19202580 2009
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. 56 61 54
18946062 2008
Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. 54 61 56
18275280 2008
Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. 56 61
16247433 2005
Risk Factors Associated With Invasive Fungal Infections in Kidney Transplant Patients. 61 42
31836132 2020
Accuracy of serological tests for diagnosis of chronic pulmonary aspergillosis: A systematic review and meta-analysis. 61 42
32182249 2020
Human dectin-1 deficiency and mucocutaneous fungal infections. 6
19864674 2009
TLR polymorphisms and the risk of invasive fungal infections. 56
18946070 2008
Identification of a human homologue of the dendritic cell-associated C-type lectin-1, dectin-1. 56
11470510 2001
Pulmonary aspergilloma: from classification to management. 42
31799858 2020
Susceptibility of mice genetically deficient in SP-A or SP-D gene to invasive pulmonary aspergillosis. 54 61
20413160 2010
Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. 54 61
19827955 2009
Identification of Aspergillus species in oral tissue samples of patients with hematologic malignancies by in situ hybridization: a preliminary report. 54 61
18718399 2008
Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis. 54 61
17335555 2007
Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. 54 61
17311505 2007
Chemokines in allergic aspergillosis--from animal models to human lung diseases. 54 61
17168792 2006
[Clinical analysis of chronic pulmonary aspergillosis and discovery of an elastase inhibitor]. 61 54
16940951 2006
[A case of idiopathic pulmonary upper lobe fibrosis complicated by invasive pulmonary aspergillosis]. 61 54
12772600 2003
[Successful treatment of invasive pulmonary aspergillosis with G-CSF and M-CSF during long-term bone marrow suppression in hypoplastic leukemia]. 61 54
11979751 2002
Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. 54 61
11474427 2001
Recombinant human macrophage colony-stimulating factor augments pulmonary host defences against Aspergillus fumigatus. 54 61
11500084 2001
A 1.1-kb duplication in the p67-phox gene causes chronic granulomatous disease. 54 61
11499676 2001
Protective role of lung surfactant protein D in a murine model of invasive pulmonary aspergillosis. 61 54
11254642 2001
Macrophage inflammatory protein-1 alpha is a critical mediator of host defense against invasive pulmonary aspergillosis in neutropenic hosts. 61 54
10878372 2000
[Aspergillosis: Mechanisms of pathogenicity implicated and approach to laboratory diagnosis.]. 54 61
17655396 1998
Lung surfactant proteins A and D can inhibit specific IgE binding to the allergens of Aspergillus fumigatus and block allergen-induced histamine release from human basophils. 61 54
9367408 1997
Polymerase chain reaction amplification of Asp f I and alkaline protease genes from fungus balls: clinical application in pulmonary aspergillosis. 61 54
9058095 1997
[Invasive pulmonary aspergillosis in a patient with acute leukemia--the role of neutrophil elastase in in cavity formation]. 54 61
8691669 1996
[Protective effect of human macrophage colony-stimulating factor on fungal infection (2). In vitro effect of human macrophage colony-stimulating factor on systemic aspergillosis and in vitro effect on the activities of macrophage]. 61 54
7602192 1995
Western blot detection of IgG anti-Aspergillus fumigatus elastase in sera of patients with aspergillosis. 54 61
7965494 1994
Lack of vessel wall elastolysis in human invasive pulmonary aspergillosis. 61 54
1452348 1992
Control of proven pulmonary and suspected CNS aspergillus infection with itraconazole in a patient with chronic granulomatous disease. 54 61
1655460 1991
[Aspergillus mastoiditis in infected granulomatosis--a case report]. 54 61
2165779 1990
Treatment of invasive fungal diseases in cancer patients-Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). 61
32236989 2020
First case of a dog infected with Aspergillus (Phialosimplex) caninus in Australasia. 61
31852374 2020
Diagnoses and management of adult cough: An Indian Environmental Medical Association (EMA) position paper. 61
32469706 2020
Proteomic analysis revealed ROS-mediated growth inhibition of Aspergillus terreus by shikonin. 61
32485396 2020
Risk factors for mortality in patients with pulmonary mucormycosis. 61
32304253 2020
Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: A systematic review with qualitative evidence synthesis. 61
32330523 2020
Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient. 61
32343223 2020
Pulmonary tuberculosis in an immunocompetent patient with primary laryngeal aspergillosis. 61
32431816 2020
Assessment of Serum Galactomannan Test Results of Pediatric Patients With Hematologic Malignancies According to Consecutive Positivity and Threshold Level in Terms of Invasive Aspergillosis Diagnosis: Cross-Sectional Research in a Tertiary Care Hospital. 61
31725542 2020
High-volume culture and quantitative real-time PCR for the detection of Aspergillus in sputum. 61
31811917 2020
The class V myosin interactome of the human pathogen Aspergillus fumigatus reveals novel interactions with COPII vesicle transport proteins. 61
32446373 2020
Posaconazole Serum Drug Levels Associated With Pseudohyperaldosteronism. 61
31403165 2020
Omalizumab is an effective intervention in severe asthma with fungal sensitisation. 61
32561499 2020

Variations for Aspergillosis

ClinVar genetic disease variations for Aspergillosis:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CLEC1A NM_016511.4(CLEC1A):c.77G>C (p.Gly26Ala)SNV risk factor 590287 rs2306894 12:10251445-10251445 12:10098846-10098846
2 CLEC7A NM_197947.3(CLEC7A):c.714T>G (p.Tyr238Ter)SNV Benign 4466 rs16910526 12:10271087-10271087 12:10118488-10118488

Expression for Aspergillosis

Search GEO for disease gene expression data for Aspergillosis.

Pathways for Aspergillosis

Pathways related to Aspergillosis according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
13.72 TLR4 IL5 IL4 IL1B IL10 IFNG
Show member pathways
13.4 IL5 IL4 IL1B IL10 IFNG CSF3
Show member pathways
13.4 TLR9 TLR4 TLR3 TLR2 IL5 IL4
Show member pathways
13.34 IL5 IL4 IL1B IL10 CSF3 CSF1
Show member pathways
13.25 TLR9 TLR4 TLR3 TLR2 IL4 IL1B
Show member pathways
Show member pathways
13.02 TLR4 TLR3 TLR2 IL4 CSF3 CSF1
Show member pathways
12.88 IL5 IL4 IL1B IL10 IFNG
Show member pathways
11 12.82 TLR9 TLR3 TLR2 IL1B IFNG
Show member pathways
Show member pathways
12.74 TLR9 TLR4 TLR3 TLR2 IL1B
Show member pathways
12.68 TLR4 TLR2 IL5 IL4 IL1B IL10
Show member pathways
12.68 TLR9 TLR4 TLR2 IL5 IL4 IL1B
16 12.65 TLR9 TLR3 TLR2 IL4 IL1B IL10
Show member pathways
12.63 TLR9 TLR4 TLR3 TLR2 IL1B
Show member pathways
12.5 IL5 IL4 IL10 IFNG CSF3
Show member pathways
Show member pathways
12.36 IL10 CSF1 CCR6 CCL3
Show member pathways
12.36 IL4 IL1B IFNG CSF1
Show member pathways
12.36 TLR4 TLR2 IL4 IL1B IL10 IFNG
23 12.34 TLR9 TLR4 TLR2 IL1B
Show member pathways
Show member pathways
12.31 IL5 IL4 IL1B IL10 IFNG
Show member pathways
12.3 TLR9 TLR4 TLR3 TLR2
27 12.29 TLR9 TLR4 TLR2 IL1B IL10 IFNG
28 12.28 TLR9 TLR4 TLR3 TLR2 IFNG
Show member pathways
12.25 TLR9 IL1B IL10 CLEC7A
Show member pathways
Show member pathways
12.15 TLR9 TLR4 TLR3 TLR2 IL5 IL1B
33 12.1 IL5 IL4 IL10 IFNG CSF3 CSF1
Show member pathways
35 12.07 TLR4 IL4 IL1B IFNG
Show member pathways
12.04 IL4 IL1B IFNG CCL3
37 12.04 TLR4 TLR2 IL1B IL10 IFNG
38 12.02 IL5 IL4 IL1B CSF3 CSF1
39 11.97 TLR4 TLR2 IL1B IFNG CSF1 CCL3
40 11.94 TLR9 TLR4 TLR3 TLR2 CLEC7A
Show member pathways
11.94 TLR9 TLR4 TLR3 TLR2 IL1B IL10
42 11.85 TLR9 IL1B IL10 IFNG CSF1
43 11.82 IL5 IL4 IFNG
Show member pathways
11.82 TLR9 TLR4 TLR3 TLR2 IL4 IL1B
45 11.79 TLR4 IL1B IL10
Show member pathways
11.79 IL5 IL4 IFNG
47 11.73 PTX3 IL5 IL4 IL1B CSF3 CCL3
48 11.7 IL5 IL4 IL10
49 11.65 TLR4 TLR2 IL1B
50 11.65 TLR4 TLR2 IL1B IFNG CSF1

GO Terms for Aspergillosis

Cellular components related to Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TLR9 SFTPD PTX3 MBL2 IL5 IL4
2 cell surface GO:0009986 9.76 TLR4 TLR3 TLR2 MBL2 ELANE CLEC7A
3 endosome membrane GO:0010008 9.56 TLR9 TLR4 TLR3 CFTR
4 extracellular space GO:0005615 9.44 TLR3 SFTPD PTX3 MBL2 IL5 IL4

Biological processes related to Aspergillosis according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.38 TLR9 TLR4 TLR3 TLR2 IL5 IL4
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.3 TLR9 TLR4 TLR3 TLR2 IL4 IL1B
3 immune system process GO:0002376 10.26 TLR9 TLR4 TLR3 TLR2 SFTPD MBL2
4 positive regulation of cell proliferation GO:0008284 10.21 IL5 IL4 IL1B IFNG CSF3 CSF1
5 innate immune response GO:0045087 10.16 TLR9 TLR4 TLR3 TLR2 SFTPD PTX3
6 cytokine-mediated signaling pathway GO:0019221 10.14 IL5 IL4 IL1B IL10 CSF3 CSF1
7 defense response to bacterium GO:0042742 10.12 TLR9 TLR4 TLR3 SFTPD MBL2 IL10
8 positive regulation of cell migration GO:0030335 10.09 IL4 IL1B CSF1 CLEC7A CCL3
9 response to lipopolysaccharide GO:0032496 10.07 TLR4 TLR2 IL1B IL10 ELANE
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.06 TLR9 TLR4 TLR3 TLR2 IL1B
11 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.03 TLR9 TLR4 TLR3 IL1B
12 cellular response to lipopolysaccharide GO:0071222 10.03 TLR4 IL1B IL10 CSF3
13 positive regulation of DNA-binding transcription factor activity GO:0051091 10 IL5 IL1B IL10 CSF3
14 cellular response to interferon-gamma GO:0071346 9.98 TLR4 TLR3 TLR2 CCL3
15 positive regulation of JNK cascade GO:0046330 9.98 TLR9 TLR4 TLR3 IL1B
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.98 TLR9 TLR4 TLR3 TLR2 IL1B
17 positive regulation of interleukin-6 production GO:0032755 9.97 TLR9 TLR4 TLR3 TLR2 IL1B
18 positive regulation of gene expression GO:0010628 9.96 TLR9 TLR4 TLR3 TLR2 IL4 IL1B
19 positive regulation of interleukin-6 secretion GO:2000778 9.95 TLR4 TLR2 IL1B IFNG
20 positive regulation of B cell proliferation GO:0030890 9.94 TLR9 TLR4 IL5 IL4
21 lipopolysaccharide-mediated signaling pathway GO:0031663 9.94 TLR4 TLR2 IL1B CCL3
22 microglial cell activation GO:0001774 9.93 TLR3 TLR2 IL4 IFNG
23 positive regulation of interferon-beta production GO:0032728 9.93 TLR9 TLR4 TLR3 TLR2
24 positive regulation of tumor necrosis factor production GO:0032760 9.93 TLR9 TLR4 TLR3 TLR2 CCL3
25 cellular response to mechanical stimulus GO:0071260 9.92 TLR4 TLR3 IL1B
26 negative regulation of osteoclast differentiation GO:0045671 9.92 TLR4 TLR3 IL4 CCL3
27 positive regulation of interleukin-10 production GO:0032733 9.92 TLR9 TLR4 TLR2 IL4
28 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.91 TLR9 TLR4 TLR3
29 positive regulation of chemokine production GO:0032722 9.9 TLR9 TLR4 TLR3 TLR2
30 toll-like receptor signaling pathway GO:0002224 9.89 TLR9 TLR4 TLR3 TLR2 SFTPD
31 negative regulation of interleukin-6 production GO:0032715 9.88 TLR9 TLR4 IL10
32 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.88 TLR9 TLR4 TLR2
33 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.86 TLR9 TLR4 TLR2 IFNG
34 positive regulation of tumor necrosis factor biosynthetic process GO:0042535 9.85 TLR4 IFNG CLEC7A
35 positive regulation of interferon-gamma biosynthetic process GO:0045078 9.85 TLR9 TLR3 CLEC7A
36 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.85 TLR9 TLR4 ELANE CLEC7A
37 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TLR4 PTX3 IL1B IFNG CLEC7A
38 response to molecule of bacterial origin GO:0002237 9.83 TLR9 TLR2 IL10
39 positive regulation of interferon-beta biosynthetic process GO:0045359 9.83 TLR9 TLR4 TLR3
40 positive regulation of chemokine biosynthetic process GO:0045080 9.83 TLR3 IL4 IL1B IFNG
41 positive regulation of interleukin-8 production GO:0032757 9.8 TLR9 TLR4 TLR3 TLR2 IL1B
42 positive regulation of phagocytosis GO:0050766 9.8 SFTPD PTX3 MBL2 IL1B IFNG CLEC7A
43 positive regulation of toll-like receptor signaling pathway GO:0034123 9.79 TLR9 TLR3 TLR2
44 I-kappaB phosphorylation GO:0007252 9.78 TLR9 TLR4 TLR3 TLR2
45 positive regulation of interleukin-12 production GO:0032735 9.77 TLR9 TLR4 TLR3 TLR2 IFNG
46 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.75 IL1B CLEC7A
47 regulation of cytokine secretion GO:0050707 9.75 TLR9 TLR2
48 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.75 IL4 IL10
49 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.74 TLR9 IL1B
50 leukocyte migration involved in inflammatory response GO:0002523 9.74 ELANE CCR6

Molecular functions related to Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.36 TLR9 TLR4 TLR3 TLR2 SFTPD PTX3
2 identical protein binding GO:0042802 10.02 TLR4 TLR3 TLR2 SFTPD PTX3 CSF1
3 signaling receptor activity GO:0038023 9.76 TLR4 TLR3 TLR2 CCR6
4 carbohydrate binding GO:0030246 9.73 SFTPD MBL2 CLEC7A CLEC1A
5 lipopolysaccharide binding GO:0001530 9.5 TLR4 TLR2 SFTPD
6 lipopolysaccharide receptor activity GO:0001875 9.37 TLR4 TLR2
7 growth factor activity GO:0008083 9.35 IL5 IL4 IL10 CSF3 CSF1
8 pattern recognition receptor activity GO:0038187 9.33 TLR9 TLR2 CLEC7A
9 (1->3)-beta-D-glucan binding GO:0001872 9.26 PTX3 CLEC7A
10 cytokine activity GO:0005125 9.23 IL5 IL4 IL1B IL10 IFNG CSF3

Sources for Aspergillosis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....